A new measurement of heart function developed at UVA Health could improve survival for people with heart failure by identifying high-risk patients who require tailored treatments, according to a new study.
The study is the first to show a survival benefit from wireless pressure monitoring sensors implanted in the pulmonary arteries. Pulmonary artery proportional pulse pressure, or PAPP, is a new measure of heart function that can identify patients at very high risk of hospitalisation or death from systolic heart failure or pulmonary hypertension (high blood pressure in the heart and lungs).
Previous work showed that patients with low PAPPs were at much higher risk than those with higher PAPPs, so the researchers tested whether these benefits were maintained in patients undergoing implantation of pressure sensors that continuously monitor pressure in the pulmonary artery.
“We found that PAPP is a very good measure of how stiff or compliant the pulmonary arteries are. The stiffness of the pulmonary arteries determines how much resistance the right side of the heart has overcome to pump blood effectively to the lungs,” said Sula Mazimba, MD, MPH, a heart failure expert at UVA Health and the School of Medicine. “The importance of this simple measure is that it can identify patients that are at greatest risk of dying or being hospitalised. This allows us to tailor more aggressive treatments.”
Heart failure causes more than 1 million hospital admissions each year, and approximately half of patients die within five years of diagnosis.
The new study evaluated the benefits of PAPP monitoring in patients with systolic heart failure, where the left ventricle is weak, as well as those with pulmonary hypertension.
To find out if PAPP monitoring could predict outcomes in these patients, Dr Mazimba and colleagues analysed data from 550 participants in the CHAMPION clinical trial, whose participants were randomised to receive an implantable, wireless heart monitor called the CardioMEMS HF System.
They found that participants with a below-average PAPP had a significantly higher risk of hospitalisation or death compared with those with higher PAPPs. Furthermore, the monitoring reduced the risk of death for those with low PAPPs by 46% annually during two to three years of follow-up.
“The implications of this study are highly significant,” said co-investigator Kenneth Bilchick, MD, MS, a cardiologist at UVA Health. “We now have identified a specific group of patients who appear to have a marked improvement in survival with implantation of these pulmonary artery wireless monitors. As a result, the findings of the study could maximise the impact of this technology for a large number of potential candidate patients. This is an excellent example of how secondary analyses of clinical databases maintained by the National Institutes of Health can result in novel and personalised approaches to patient care.”
The researchers say further study is necessary to gauge the full potential of PAPP monitoring to improve care for patients with heart failure, but early results were encouraging.
“In the past, the function of the right chamber of the heart was often ignored and considered to be inconsequential to the overall performance of the heart, but we are now learning that this is not the case,” Dr Mazimba said. “Having tools that signal when the right side of the heart is under strain may aid clinicians to adopt timely tailored treatments for heart-failure patients.”
Source: UVA Health
